TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9806696
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral dextromethorphan
Study: 8529331
Drug: Fosinopril (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (intravenous and oral)
Study: 8529331
Drug: Fosinopril (oral)
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril (oral)
Study: 2131458
Drug: Chewable tablets
Normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablets containing pyridoxine and heat‐killed lactic bacteria
Study: 2132274
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets with pyridoxine only
Study: 7115241
Drug: Autogenic-feedback training
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic-feedback training (AFT) for highly susceptible subjects (Treatment Group I)
Study: 7115241
Drug: Autogenic-feedback training
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogenic-feedback training (AFT) for moderately susceptible subjects (Treatment Group II)
Study: 31420787
Drug: PL‐ASA 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL‐ASA 325 mg
Study: 31420787
Drug: PL‐ASA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL‐ASA 650 mg
Study: 31420787
Drug: IR‐ASA 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐ASA 325 mg
Study: 31420787
Drug: IR‐ASA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐ASA 650 mg
Study: 25826678
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid administration (S-group)
Study: 25826678
Drug: Reduced fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced fluid administration (R-group)
Study: 24890250
Drug: Structured preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured preparation meeting and access to population-based data
Study: 21789881
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily oral DHEA for 28 days
Study: 11815423
Drug: Short-term estrogen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term estrogen administration (25 mg of conjugated equine estrogens IV)
Study: 11815423
Drug: Long-term hormone
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term hormone replacement therapy (HRT)
Study: 10412515
Drug: rh-GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-GH therapy (0.250 IU/Kg/week)
Study: 10412515
Drug: rh-GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-GH therapy
Study: 7748051
Drug: Nondihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondihydropyridine calcium antagonists
Study: 7748051
Drug: Dihydropyridine calcium
Normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium antagonists
Study: 28776117
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (0.25 mg/12 h) administered the day before hCG trigger
Study: 28776117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no double dose of GnRH antagonist)
Study: 19154566
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (0.8 mg folic acid, 0.5 mg cyanocobalamin, and 3 mg pyridoxine daily for 6 months)
Study: 26386802
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin
Study: 11150025
Drug: low‐molecular‐weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐molecular‐weight heparin
Study: 9456420
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (1 mg)
Study: 7653747
Drug: 0.125% cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% cetirizine nasal spray
Study: 7653747
Drug: 0.06% cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% cetirizine nasal spray
Study: 7653747
Drug: 0.25% cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% cetirizine nasal spray
Study: 3670682
Drug: Thymomodulin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin (120 mg/die for 20 days/month for 4 months)
Study: 3670682
Drug: Thymomodulin in
Normalized name: thymomodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin in association with vaccine (120 mg/die for 20 days/month for 4 months)
Study: 3670682
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of vaccine-thymomodulin
Study: 31128008
Drug: Preoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative infusion chemotherapy combined with hyperthermia
Study: 12780755
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/m2)
Study: 12780755
Drug: Dexamethasone (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6.5 mg/m2)
Study: 11214010
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment for acute myocardial infarction in left bundle branch block
Study: 11214010
Drug: Thrombolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic treatment for acute myocardial infarction in right bundle branch block
Study: 8939767
Drug: 1 of
Normalized name: lisocabtagene maraleucel, CD8 component, 1 of 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 of 2 doses of vitamin D+Ca
Study: 3976636
Drug: Both metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both metoclopramide doses
Study: 31258019
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, anemic mothers)
Study: 31258019
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, non-anemic mothers)
Study: 31258019
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation at a dose of 2 mg kg-1 from 36 hours of age (N=50, anemic and non-anemic mothers)
Study: 25872790
Drug: Colistin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin 4.5 MU as a loading dose, followed by 3 MU every eight hours, combined with levofloxacin
Study: 25872790
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every eight hours, combined with levofloxacin
Study: 24225149
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care + smartphone application (Glucose Buddy) with weekly text-message feedback from a Certified Diabetes Educator
Study: 11176979
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost for 3 months (n = 8)
Study: 11176979
Drug: Alternative medication
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative medication for 3 months (n = 9)
Study: 7941592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no KLH treatment)
Study: 18457786
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (FCs with monthly contact from Healthy Eating Coordinator)
Study: 18457786
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (FCs without monthly contact from Healthy Eating Coordinator)
Study: 12635790
Drug: Resorbable Shuttle
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resorbable Shuttle Stop (HC Implants, BV. Leiden, The Netherlands)
Study: 9298778
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g daily for 5 days)
Study: 8509527
Drug: ECT twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT twice a week
Study: 25772212
Drug: MamaNatalie (MG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MamaNatalie (MG) - 45 minutes of SVD simulation using an obstetrical abdominal-pelvic model
Study: 18410326
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release oxybutynin 5 mg once daily
Study: 16368813
Drug: Frakefamide (FF)
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frakefamide (FF) 1.22 mg/kg
Study: 16368813
Drug: Morphine (M-large)
Normalized name: morphine sulfate Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (M-large) 0.44 mg/kg
Study: 16368813
Drug: Placebo (Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Sodium chloride 9 mg/mL)
Study: 8975955
Drug: Fiber supplement
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber supplement (Plantago Ovata)
Study: 20690893
Drug: Oxybutynin immediate-release
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin immediate-release 15 mg/day
Study: 15948985
Drug: Pimecrolimus 10
Normalized name: pimecrolimus 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 10 mg b.d.
Study: 15948985
Drug: Pimecrolimus 20
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus 20 mg b.d.
Study: 15948985
Drug: Pimecrolimus 30
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus 30 mg b.d.
Study: 12563622
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (94 mg Ox + 26 mg Ca)
Study: 12563622
Drug: Milk chocolate
Normalized name: Meritene Milk Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk chocolate (94 mg Ox + 430 mg Ca)
Study: 1846787
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 6, 35, 200 or 1200 m-units min-1 m-2 for 2 hours
Study: 1846787
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at higher rates
Study: 29500678
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message support (daily text message for 1 year)
Study: 8583793
Drug: TCV-116 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 2.5 mg
Study: 8583793
Drug: TCV-116 5
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-116 5 mg
Study: 6277642
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (5 mg i.m.)
Study: 6277642
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (20 mg i.m.)
Study: 6277642
Drug: Alcohol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.5 g/kg)
Study: 21345942
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg/day)
Study: 11740193
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg once daily for the first 2 weeks)
Study: 9922474
Drug: Pamidronate infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate infusions (30 or 45 mg weekly)
Study: 9922474
Drug: Pamidronate infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate infusions (30 or 45 mg every three months or 90 mg every six months)
Study: 8118635
Drug: Bronchodilator (BD)
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (BD) treatment
Study: 4890207
Drug: Azathioprine-prednisolone combination
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine-prednisolone combination
Study: 4890207
Drug: Azathioprine-prednisolone treatment
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine-prednisolone treatment prolonged to one year
Study: 28371937
Drug: Naldemedine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.1 mg
Study: 28371937
Drug: Naldemedine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldemedine 0.4 mg
Study: 9625095
Drug: Luteolin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteolin (279 micromol/L)
Study: 9625095
Drug: Myricetin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myricetin (279 micromol/L)
Study: 9625095
Drug: Quercetin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (279 micromol/L)
Study: 9625095
Drug: Kaempferol (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaempferol (279 micromol/L)
Study: 9625095
Drug: Quercitrin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercitrin (279 micromol/L)
Study: 9625095
Drug: Apigenin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apigenin (279 micromol/L)
Study: 9625095
Drug: Quercetin-3-glucoside (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-3-glucoside (279 micromol/L)
Study: 9625095
Drug: Rutin (279
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin (279 micromol/L)
Study: 9625095
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (279 micromol/L)
Study: 9625095
Drug: Quercetin (23.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (23.2 micromol/L)
Study: 9625095
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (23.2 micromol/L)
Study: 9625095
Drug: Quercetin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin and Vitamin C (23.2 micromol/L each)
Study: 3375957
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for lung cancer in asbestos-exposed patients
Study: 30388439
Drug: Spermidine-rich plant
Normalized name: spermidine
DrugBank: Spermidine (DB03566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermidine-rich plant extract supplement
Study: 27342073
Drug: Combined Training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Training (HIIT + RT): Combination of both HIIT and RT interventions.
Study: 24941837
Drug: Integrated Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese medical treatment (CM treatment) as maintenance therapy
Study: 24941837
Drug: Western drug
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western drug chemotherapy (Gemcitabine or Alimta or docetaxel)
Study: 22619193
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 4 mg/mL dexamethasone sodium phosphate
Study: 22619193
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of normal saline (placebo)
Study: 20927003
Drug: Constraint Induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint Induced Movement Therapy
Study: 16085220
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of a soluble TNF receptor (TNFR:Fc, etanercept, Enbrel) 25mg subcutaneously, twice weekly for 2 weeks
Study: 11918622
Drug: Atorvastatin (hydroxymethylglutaryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (hydroxymethylglutaryl coenzyme A reductase inhibitor)
Study: 10400847
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 25 microgram once daily
Study: 10400847
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 100 microgram once daily
Study: 10400847
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 200 microgram once daily
Study: 10400847
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 84 microgram twice daily (168 microgram/day)
Study: 17503885
Drug: Trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20 mg every 8 hours, starting 15 days before PCI and continuing for 3 months after the procedure.
Study: 15731325
Drug: Subarachnoid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid block with 2.5 mg hyperbaric bupivacaine + 25 mug fentanyl + 1 mL 10% glucose (Group S)
Study: 15731325
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block with 7 mL 2% mepivacaine (Group P)
Study: 7814237
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vitamin C per day
Study: 2550176
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (2 x 2 mg puffs twice a day)
Study: 368333
Drug: Clonidine (Dixarit)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (Dixarit) at a dose of up to 0.15 mg daily
Study: 27799203
Drug: ABX464 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (50 mg) under fed conditions
Study: 27799203
Drug: ABX464 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (50 mg) under fasted conditions
Study: 27799203
Drug: ABX464 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (50 mg)
Study: 26761561
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily physical activity (usual group; UG)
Study: 21504485
Drug: CF101 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 (2 mg)
Study: 19910566
Drug: bicarbonate-buffered peritoneal
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bicarbonate-buffered peritoneal dialysis solution (bicPDF)
Study: 8150100
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg two times per day for 9 months)
Study: 8150100
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg for 9 months)
Study: 29578097
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV vaccine (1-180 days)
Study: 29578097
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV vaccine (1-60-180 days)
Study: 28688643
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch applied around the surgical wound
Study: 28688643
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with adhesive sides of the lidocaine patches shielded with waterproof films
Study: 22612364
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL rhPDGF-BB
Study: 22612364
Drug: 1.0 mg/mL
Normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/mL rhPDGF-BB
Study: 20979997
Drug: Recombinant luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant luteinizing hormone (LH) luteal supplementation
Study: 18364502
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing (cutoff of 1 pg/mL)
Study: 18364502
Drug: HPV testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV testing (cutoff of 2 pg/mL)
Study: 16293958
Drug: Nebulized flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized flunisolide (1 mg) + salbutamol/ipratropium bromide (1,875/375 microg) b.i.d.
Study: 10080566
Drug: D-cycloserine 100
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 100 mg/day
Study: 7744141
Drug: Zoladex 10.8-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex 10.8-mg depot administered every 12 weeks
Study: 7744141
Drug: Zoladex 3.6-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex 3.6-mg depot administered every 28 days
Study: 2405137
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (6 months) before the initiation of vitamin D therapy
Study: 2405137
Drug: Serum concentrations
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum concentrations of alkaline phosphatase, parathyroid hormone, and bicarbonate
Study: 19819688
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (Group A)
Study: 19819688
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (Group B)
Study: 31977628
Drug: 0.04 μg/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 μg/kg/min norepinephrine infusion